Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by 'writing' DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Company profile
Ticker
TWST
Exchange
Website
CEO
Emily Leproust
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
Corporate docs
Subsidiaries
Twist Bioscience Worldwide • Genome Compiler Corporation • Twist Bio Computing, LLC • Twist Pharmaceutical • Twist Bioscience Singapore PTE. LTD. • iGenomX International • Twist Bioscience Netherlands B.V. • AbX Biologics, Inc. ...
IRS number
462058888
TWST stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
8 Feb 23
10-Q
2023 Q1
Quarterly report
7 Feb 23
8-K
Twist Bioscience Reports Fiscal First Quarter 2023 Financial Results
3 Feb 23
DEF 14A
Definitive proxy
6 Jan 23
S-8
Registration of securities for employees
28 Nov 22
10-K
2022 FY
Annual report
28 Nov 22
8-K
Amendments to Articles of Incorporation or Bylaws
18 Nov 22
8-K
Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2022 Financial Results
18 Nov 22
8-K
Twist Bioscience Addresses Misleading Short-Seller Report
15 Nov 22
8-K
Departure of Directors or Certain Officers
26 Oct 22
Transcripts
TWST
Earnings call transcript
2023 Q1
3 Feb 23
TWST
Earnings call transcript
2022 Q4
18 Nov 22
TWST
Earnings call transcript
2022 Q3
5 Aug 22
TWST
Earnings call transcript
2022 Q2
6 May 22
TWST
Earnings call transcript
2022 Q1
4 Feb 22
TWST
Earnings call transcript
2021 Q3
6 Aug 21
TWST
Earnings call transcript
2021 Q2
8 May 21
TWST
Earnings call transcript
2021 Q1
5 Feb 21
TWST
Earnings call transcript
2020 Q4
23 Nov 20
TWST
Earnings call transcript
2020 Q4
23 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Sep 22 | Sep 21 | Sep 20 | Sep 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 319.09 mm | 319.09 mm | 319.09 mm | 319.09 mm | 319.09 mm | 319.09 mm |
| Cash burn (monthly) | 20.39 mm | (no burn) | 14.88 mm | 18.62 mm | 18.02 mm | 10.98 mm |
| Cash used (since last report) | 54.90 mm | n/a | 40.06 mm | 50.14 mm | 48.53 mm | 29.57 mm |
| Cash remaining | 264.19 mm | n/a | 279.04 mm | 268.95 mm | 270.56 mm | 289.52 mm |
| Runway (months of cash) | 13.0 | n/a | 18.8 | 14.4 | 15.0 | 26.4 |
Institutional ownership, Q4 2022
| 13F holders | Current |
|---|---|
| Total holders | 193 |
| Opened positions | 26 |
| Closed positions | 52 |
| Increased positions | 78 |
| Reduced positions | 48 |
| 13F shares | Current |
|---|---|
| Total value | 1.42 tn |
| Total shares | 64.18 mm |
| Total puts | 74.10 k |
| Total calls | 226.90 k |
| Total put/call ratio | 0.3 |
| Largest owners | Shares | Value |
|---|---|---|
| ARK Investment Management | 6.70 mm | $159.55 bn |
| BLK Blackrock | 5.49 mm | $130.66 bn |
| Vanguard | 5.23 mm | $124.51 bn |
| STT State Street | 4.43 mm | $105.39 bn |
| JPM JPMorgan Chase & Co. | 3.90 mm | $92.74 bn |
| FMR | 3.09 mm | $73.50 bn |
| CMTDF Sumitomo Mitsui Trust | 2.93 mm | $69.86 bn |
| Nikko Asset Management Americas | 2.93 mm | $69.77 bn |
| William Blair Investment Management | 2.04 mm | $48.52 bn |
| ILMN Illumina | 1.70 mm | $240.49 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 13 Mar 23 | Dennis Cho | Common Stock | Payment of exercise | Dispose F | No | No | 16.83 | 103 | 1.73 k | 19,688 |
| 13 Mar 23 | Dennis Cho | Common Stock | Payment of exercise | Dispose F | No | No | 16.83 | 103 | 1.73 k | 19,688 |
| 17 Feb 23 | Kevin Bruce Yankton | Common Stock | Payment of exercise | Dispose F | No | No | 22.52 | 60 | 1.35 k | 10,073 |
| 17 Feb 23 | Green Paula | Common Stock | Payment of exercise | Dispose F | No | No | 22.52 | 260 | 5.86 k | 22,615 |
| 17 Feb 23 | Finn Patrick John | Common Stock | Payment of exercise | Dispose F | No | No | 22.52 | 1,027 | 23.13 k | 101,532 |
News
Stocks That Hit 52-Week Lows On Friday
10 Mar 23
Twist Bioscience Announced An Integrated Offering Of Antibody Discovery Services Available To Customers
9 Mar 23
Stocks That Hit 52-Week Lows On Wednesday
1 Mar 23
Goldman Sachs Maintains Neutral on Twist Bioscience, Lowers Price Target to $43
6 Feb 23
Baird Maintains Outperform on Twist Bioscience, Lowers Price Target to $29
6 Feb 23
Press releases
Lifshitz Law PLLC Announces Investigations of Twist Bioscience Corporation (NASDAQ: TWST), Sunlight Financial Holdings Inc. (NYSE: SUNL), Gaia, Inc. (NASDAQ: GAIA), and Daktronics, Inc. (NASDAQ: DAKT)
17 Mar 23
TWIST ALERT: Bragar Eagel & Squire, P.C. is Investigating Twist Bioscience Corp on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
16 Mar 23
Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches
9 Mar 23
Investors who hold shares of Twist Bioscience Corporation (NASDAQ: TWST) long should contact the Shareholders Foundation in connection with the Lawsuit against Twist Bioscience Corporation
14 Feb 23
Twist Bioscience Publishes Data on VHH Single Domain Antibody Discovery Using New Methodology on Optofluidic Platform
14 Feb 23